1. Expanding Treatment Horizons in Head and Neck Cancer: TRK Inhibitors

3. This program will include a discussion of investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

4. Introduction

5. Prevalence

6. Larotrectinib

7. Response Rate

8. Outcomes

9. Select Treatment-Related Adverse Events

10. Larotrectinib in Thyroid and Salivary Gland Cancers

11. Results

12. Entrectinib

13. Entrectinib (cont)

14. Acquired Resistance

15. Novel Approaches

16. Detecting NTRK Gene Fusions

17. Diagnostic Testing

18. Diagnostic Testing in Salivary Gland Cancers

19. Diagnostic Testing in Thyroid Cancer

20. Future Questions

21. Unknowns

22. Implications for the Future

23. Concluding Remarks

24. Abbreviations

25. Abbreviations (cont)